Key regions: United Kingdom, Brazil, Europe, France, Canada
The Anti-Fibrinolytic Drugs market in BRICS has been experiencing steady growth over the past few years.
Customer preferences: One of the main reasons for this growth is the increasing prevalence of bleeding disorders and surgical procedures in these countries. Patients suffering from hemophilia, liver disease, and other bleeding disorders require anti-fibrinolytic drugs to prevent excessive bleeding. Additionally, the rise in the number of surgeries being performed in BRICS countries has led to an increase in demand for these drugs.
Trends in the market: Brazil, Russia, India, China, and South Africa have been witnessing a significant increase in the number of surgeries being performed. This has led to a rise in demand for anti-fibrinolytic drugs. Brazil and Russia have been experiencing the highest growth in the market due to the increasing number of surgeries being performed in these countries. India and China are also witnessing steady growth due to the rising prevalence of bleeding disorders and the increasing number of surgeries.
Local special circumstances: In Brazil, the government has been investing heavily in the healthcare sector, which has led to an increase in the number of surgeries being performed. The country has also been witnessing a rise in medical tourism, which has further contributed to the growth of the market. In Russia, the government has been focusing on improving the healthcare infrastructure, which has led to an increase in the number of surgeries being performed. In India, the rise in disposable income and the increasing awareness about bleeding disorders have led to an increase in demand for anti-fibrinolytic drugs. In China, the government has been promoting the use of generic drugs, which has led to an increase in the availability of anti-fibrinolytic drugs.
Underlying macroeconomic factors: The growth of the Anti-Fibrinolytic Drugs market in BRICS can also be attributed to the underlying macroeconomic factors in these countries. The rise in disposable income, increasing healthcare expenditure, and the growing middle class population have all contributed to the growth of the market. Additionally, the increasing focus on research and development activities by pharmaceutical companies in these countries has led to the development of new and innovative drugs, which has further boosted the growth of the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
